PHARMACYTE BIOTECH, INC. (PMCB) Return on equity 2017–2026
PHARMACYTE BIOTECH, INC. (PMCB) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-58.3%FY2026 · since FY2017: -54.9% → -58.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -58.3% | -117.4 pp |
| FY2025 | 59.1% | +57.9 pp |
| FY2024 | 1.2% | +7.1 pp |
| FY2023 | -5.9% | -1.2 pp |
| FY2022 | -4.7% | +48.5 pp |
| FY2021 | -53.2% | +22.0 pp |
| FY2020 | -75.2% | +5.5 pp |
| FY2019 | -80.7% | +37.7 pp |
| FY2018 | -118.4% | -63.4 pp |
| FY2017 | -54.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice